Tag: Simran Gill (CFA)
-
Abattis Bioceuticals (ATT.C): A grift building over several years until regulators couldn’t ignore it anymore
Several years ago, when Equity.Guru boss Chris Parry was writing at Stockhouse, he was called out to a new client – a company called Abattis Bioceutical (ATT.C). Abattis execs had just signed a marketing deal with Stockhouse to help tell their story to investors, and were excited for what might follow. As Parry tells it,…
